Congress trades
AngioDynamics, Inc. (ANGO)
About AngioDynamics, Inc.
from the company's filings and listing- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Chief executive
- James C. Clemmer
- Employees
- 632
- Listed since
- Jun 1, 2004
- Market value
- $633.2M
- Price to earnings
- -
- Earnings per share
- -$0.88
- Dividend yield
- -
Earnings
6 reported quarters · next on Oct 1, 2026| Quarter | EPS | EPS expected | Revenue | Revenue expected | Result |
|---|---|---|---|---|---|
| Q4 FY2026reported Jul 14, 2026 | -$0.07 | -$0.11 | $86.6M | $80.2M | EPS beatRevenue beat |
| Q3 FY2026reported Apr 2, 2026 | -$0.07 | -$0.11 | $78.4M | $76.8M | EPS beatRevenue beat |
| Q2 FY2026reported Jan 6, 2026 | -$0.15 | -$0.10 | $79.4M | $76.4M | EPS missRevenue beat |
| Q1 FY2026reported Oct 2, 2025 | -$0.10 | -$0.14 | $75.7M | $76.3M | EPS beatRevenue in line |
| Q4 FY2025reported Jul 15, 2025 | -$0.03 | -$0.13 | $80.2M | $74.3M | EPS beatRevenue beat |
| Q3 FY2025reported Apr 2, 2025 | $0.03 | -$0.13 | $72.0M | $74.3M | EPS beatRevenue miss |
Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag marked GAAP compares a GAAP figure the company reported with an adjusted consensus, two different measures, so a one-time gain or charge can move it either way; basis unverified means we could not classify the reported figure. A flag reads n/a only when a number is missing. An estimate is a forecast made by analysts, not a company target.
Executive pay
as filed for 2025 · proxy filed Sep 25, 2025| Executive | Salary | Stock awards | Other | Total |
|---|---|---|---|---|
| James C. ClemmerPresident, CEO | $803K | $2.6M | $2.1M | $5.5M |
| Stephen A. TrowbridgeEVP, CFO | $456K | $934K | $772K | $2.2M |
| Laura PiccininiSVP & GM, Cardiovascular and International | $410K | $415K | $545K | $1.4M |
| Lawrence T. WeissSVP & Chief Legal Officer | $207K | $376K | $587K | $1.2M |
| Warren NighanSVP & GM, Global Supply Chain, Quality and Regulatory | $401K | $337K | $427K | $1.2M |
The summary compensation table from the 2025 proxy statement, current executives only. Read the filing
Institutional holders
13F positions as of Jun 30, 2026| Holder | Value | Shares | Change | Of company |
|---|---|---|---|---|
| Blackrock, Inc. | $49.5M | 3,803,232 | +3.2% | 9.16% |
| Point72 Asset Management, L.P. | $39.8M | 3,062,517 | -3.7% | 7.37% |
| Systematic Financial Management LP | $34.3M | 2,640,214 | +7.6% | 6.36% |
| Armistice Capital, LLC | $28.6M | 2,198,000 | +17.6% | 5.29% |
| Royce & Associates LP | $25.6M | 1,969,835 | +28.8% | 4.74% |
| Broadfin Holdings LLC | $23.7M | 1,818,533 | -12.1% | 4.38% |
| Vanguard Capital Management LLC | $22.0M | 1,694,716 | -1.9% | 4.08% |
| Weber Capital Management LLC /Adv | $17.6M | 1,356,602 | -1.2% | 3.27% |
| Nuveen, LLC | $15.6M | 1,199,358 | -1.4% | 2.89% |
| Geode Capital Management, LLC | $13.3M | 1,020,658 | +3.6% | 2.46% |
| Dimensional Fund Advisors LP | $12.6M | 969,497 | +2.2% | 2.33% |
| State Street Corp | $12.5M | 958,167 | -28.2% | 2.31% |
A 13F reports long US equity positions 45 days after the quarter ends, so these are positions as they stood on Jun 30, 2026. For a manager's whole book see the fund directory.
GetSignal watches Form 4 and STOCK Act filings and pushes each one to your phone as it is published, with the history behind it. Free on iOS and Android.
Congress trades in ANGO
5 disclosures of 5 on record · median 28d of the 45 allowed| Member | Type | Action | Amount disclosed | Since the trade | Trade date | Disclosed | Delay |
|---|---|---|---|---|---|---|---|
| Debbie Wasserman SchultzDependent child | Stock | Sale | $2,000.00 | +29.6%S&P +13.6% · vs S&P 500 +16.1% | Oct 20, 2025 | Oct 24, 2025 | 4d |
| Debbie Wasserman Schultz | Stock | Sale | $1,001 - $15,000 | +78.1%S&P +22.2% · vs S&P 500 +56.0% | Jul 16, 2025 | Jul 25, 2025 | 9d |
| Debbie Wasserman SchultzDependent child | Stock | Purchase | $1,001 - $15,000 | +56.7%S&P +23.6% · vs S&P 500 +33.0% | Jun 27, 2025 | Jul 25, 2025 | 28d |
| Debbie Wasserman SchultzDependent childFiled late | Stock | Sale | $1,001 - $15,000 | -5.4%S&P +256.5% · vs S&P 500 -261.9% | Nov 8, 2016 | Dec 25, 2016 | 47d |
| Debbie Wasserman SchultzDependent childFiled late | Stock | Purchase | $1,001 - $15,000 | +23.4%S&P +265.0% · vs S&P 500 -241.6% | Apr 27, 2016 | Jul 6, 2016 | 70d |
Since the trade: the stock's move from the trade date to the latest close we hold, as of Sep 10, 2026, an estimate, with the S&P 500 over the same window and the difference against it. The figures describe the stock after the trade, not the member's result: the filing carries a band, not a fill, and a sale keeps the same sign, so a positive figure after a sale means the stock kept rising. An option row carries the underlying stock's move. A row marked n/a has no market price. Not investment advice.
Questions
Which members of Congress have traded ANGO?
Debbie Wasserman Schultz disclosed ANGO transactions in the filings shown here.
How quickly are ANGO trades disclosed?
Congressional disclosures took a median of 28 days, against the 45 the STOCK Act allows.
How to read a STOCK Act filing
WHAT THE FILING ACTUALLY SAYS
Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.
Data as of Sep 10, 2026.